Agbiotech supporters and opponents have been waiting for months for the opinion of the Advocate General of the European Court of Justice, hoping that it would settle the fateful question: do edited plants follow the same legislation as GMOs? The answer, however, does not appear to be conclusive and has been variously interpreted. Nature, The Scientist, and The Guardian are cautiously optimistic, but this Euractiv article is even more interesting. Uncertainty is the prevailing mood in this field. Continue reading
CRISPR plants are coming, and USDA is fine
The US Department of Agriculture has given the green light to five CRISPR-edited plants in the last couple of years. See the table below, published by Nature Biotechnology this month. CRISPR is set to make its commercial debut in fields in 2020, with DuPont Pioneer’s waxy corn, and hopes are high that gene editing will give us the chance of rewriting the GMO debate. Continue reading
What if the human body attacks CRISPR? Can we cheat it?
“Uh Oh. CRISPR might not work on people”. A title like this on the MIT Technology Review website is not the best way to kick-start the new year. But wait, our motto still stands: keep calm and crispr on.
2018: Happy New Edit!
2017 ends with over 3,000 CRISPR papers indexed by PubMed and 6,810,000 Google’s search results. There is no doubt that 2018 is going to be hot, with the brand new CRISPR Journal launching in 2018 and leading scientists convening at a super CRISPR meeting in Lithuania next June. Clinical trials for genetic diseases such as beta-thalassemia and Leber congenital amaurosis are expected to start, and a forthcoming European Court verdict could be a turning point for the future of edited crops. Happy new year and happy new edit then, surprisingly surprising surprises ahead!
CRISPR in 5 cartoons
Merry CRISPmas and happy new edit!
What a wonderful knife
The Swiss army knife is still the best analogy to describe what CRISPR can do, according to STAT’s top-ten, and we can’t disagree. But please take a look at this revised picture from Nature Reviews Genetics. CRISPR has learned new tricks; it’s much more than a pair of scissors by now.
The gene corrector in Nature’s top 10
2017 brightest star in CRISPR heavens is David Liu, according to Nature. Be sure not to miss this old profile from the Harvard Gazette if curious to see his funny side.
Epigenetic editing hits hat-trick

Reversing three genetic diseases in the animal model without even changing a single DNA letter. A Salk Institute team did it by bringing together two of biomedicine’s hottest trends. One is the CRISPR technique, which edits target genes through a programmable molecular machine named Cas9. The other is epigenetics, i.e., the study of chemical modifications that switch genes on and off without altering their sequence. It’s called epigenetic editing, because corrections are precise as in manuscript revision and occur at a level that is over (epi- in Greek) genetics. Continue reading
Gene drives: the experiment goes social
Choose a word to fill the gap in the sentence. “Gene drives are an ambitious experiment in …”. Genetics? Ecology? Evolution? Obviously, gene drives are all this and more. They may also represent a significant social experiment in risk communication, public engagement, participatory processes. Potential applications of this technology include controlling the transmission of vector-borne diseases and eliminating invasive species from sensitive ecosystems. We do not yet know if these genetic elements, designed to foster the preferential inheritance of a gene of interest with CRISPR’s help, will work in field trials as hoped. To find out, a green light to test this technology out of the labs will have to be negotiated with the public, stakeholders, regulators, and governments of affected countries. A first step in this direction was taken last week with the commitment to respect shared guiding principles in gene drive research and communication published in Science by the technology main sponsors and supporters. Signatory organizations are scattered around the world, from the US to India, with the Bill & Melinda Gates Foundation at the forefront with its Target Malaria project. Continue reading